CASI Pharmaceuticals News

Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks were higher Wednesday afternoon, with the NYSE Health Care Index adding 1.1% and the Health Care Select Sector SPDR Fund (XLV) rising 1.3%. The iShares Biotechnology ETF (IBB) gaine

MT Newswires12:52

CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 15 10:57

HC Wainwright & Co. : The CASI Pharmaceuticals (CASI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $6.00.

HC Wainwright & Co. : The CASI Pharmaceuticals (CASI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $6.00.

Zhitong FinanceMay 15 10:50

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $6

HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $12 to $6.

BenzingaMay 15 10:46

CASI Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 83.49% HC Wainwright & Co. $12 → $6 Maintains Buy 11/15/2023 266.97% HC Wainwright & Co. $10 →

BenzingaMay 15 10:45

Casi Pharma Spikes as FDA Clears Clinical Trial for Blood Disorder Therapy

Seeking AlphaMay 15 08:00

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GainersSINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 d

BenzingaMay 15 07:06

CASI Pharmaceuticals Gets FDA Clearance On The IND Application For CID-103 In Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the fo

BenzingaMay 15 07:04

CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 15 05:55 · Announcements

CASI Pharmaceuticals (CASI.US): The 2024 Q1 financial report achieved revenue of US$3.409 million, with a previous value of US$8.347 million, with an expected value of US$12 million; earnings per share were -0.71 dollars, the previous value was -0.45 US d

CASI Pharmaceuticals (CASI.US): The 2024 Q1 financial report achieved revenue of US$3.409 million, with a previous value of US$8.347 million, with an expected value of US$12 million; earnings per share were -0.71 dollars, the previous value was -0.45 US dollars, and the expected value was -0.05 US dollars.

Zhitong FinanceMay 14 08:11

CASI Pharmaceuticals Q1 EPS $(0.71) Misses $(0.05) Estimate, Sales $3.41M Miss $12.00M Estimate

CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.05) by 1320 percent. This is a 57.78 percent decrease over losses o

BenzingaMay 14 07:23

Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, Vs. Street Est of $12M

08:05 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M

MT NewswiresMay 14 07:05

CASI Pharmaceuticals 1Q Loss/Shr 71c >CASI

CASI Pharmaceuticals 1Q Loss/Shr 71c >CASI

Dow JonesMay 14 07:00

Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal

Seeking AlphaMay 2 13:31

CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas

On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong I

BenzingaApr 8 16:03

CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI

CASI Pharmaceuticals Gets Emergency Injunctive Relief in Dispute With Juventas Cell Therapy >CASI

Dow JonesApr 8 16:02

CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI

CASI Pharmaceuticals: Order Prohibits Juventas From Commercializing CNCT19 >CASI

Dow JonesApr 8 16:02

CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute With Juventas Cell Therapy Ltd Prohibiting Juventas From Commercializing CNCT19

On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company ("CASI" or the "Company") announced that, with respect to the Company's previously announced dispute with Juventas

BenzingaApr 8 06:34

Recap: CASI Pharmaceuticals Q4 Earnings

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCASI Pharmaceuticals misse

BenzingaMar 28 07:20

CASI Pharmaceuticals GAAP EPS of -$2.02, Revenue of $33.88M

Seeking AlphaMar 28 06:22